PF-184563

PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor. The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1328695827 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.